Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab pharmacokinetics and safety in children with moderate-to-severe atopic dermatitis
NL-OMON53683Phase 2Recruiting
- Sponsor
- LEO Pharma
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of tralokinumab in atopic dermatitis (AD) (3 arms), sponsored by LEO Pharma. Primary endpoints: Trough concentration at Week 16, Maximum concentration and 2 more. Started Sep 2022; status: recruiting.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON53683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53683.